Viewray (NASDAQ: VRAY) and BIOLASE (NASDAQ:BIOL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.
Risk and Volatility
Viewray has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500. Comparatively, BIOLASE has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500.
50.6% of Viewray shares are held by institutional investors. Comparatively, 29.3% of BIOLASE shares are held by institutional investors. 62.8% of Viewray shares are held by insiders. Comparatively, 7.1% of BIOLASE shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a breakdown of current ratings and target prices for Viewray and BIOLASE, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Viewray presently has a consensus target price of $11.58, indicating a potential upside of 37.73%. BIOLASE has a consensus target price of $2.50, indicating a potential upside of 455.56%. Given BIOLASE’s higher possible upside, analysts plainly believe BIOLASE is more favorable than Viewray.
Valuation and Earnings
This table compares Viewray and BIOLASE’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Viewray||$22.24 million||25.54||-$50.63 million||($1.13)||-7.44|
|BIOLASE||$51.81 million||0.89||-$15.37 million||($0.31)||-1.45|
BIOLASE has higher revenue and earnings than Viewray. Viewray is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.
This table compares Viewray and BIOLASE’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
BIOLASE beats Viewray on 7 of the 12 factors compared between the two stocks.
Viewray Company Profile
ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.
BIOLASE Company Profile
BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.